SCHEMBL15969020

SCHEMBL15969020

CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OCCCNC(=O)O)ccc2-n2c(C)nnc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 20/20 0.79
SMCHD1 A6NHR9 1/20 0.79
MYO1G B0I1T2 1/20 0.79
AIP O00170 1/20 0.79
AP3B1 O00203 1/20 0.79
PSMD11 O00231 1/20 0.79
CDC7 O00311 1/20 0.79
SAP18 O00422 1/20 0.79
KPNA3 O00505 1/20 0.79
PPP6C O00743 1/20 0.79
TCERG1 O14776 1/20 0.79
UBE2L6 O14933 1/20 0.79
PPP1R12A O14974 1/20 0.79
U2SURP O15042 1/20 0.79
SETD1A O15047 1/20 0.79
ARPC1B O15143 1/20 0.79
POLR1C O15160 1/20 0.79
OGT O15294 1/20 0.79
PPM1G O15355 1/20 0.79
SLC16A3 O15427 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14747051 0.98 BRD4 (0.80) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL25274977 0.98 BRD4 (0.80) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL25273351 0.97 BRD4 (0.76) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL16774020 0.95 BRD4 (0.85) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL14756339 0.94 BRD4 (0.87) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL15981838 0.94 BRD4 (0.83) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL16774047 0.94 BRD4 (0.83) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL16774286 0.94 BRD4 (0.83) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL16774026 0.94 BRD4 (0.83) BRD4SMCHD1MYO1GAIPAP3B1
SCHEMBL16773952 0.94 BRD4 (0.83) BRD4SMCHD1MYO1GAIPAP3B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243322-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME BRDT, BRD2, BRD4 BRD4 3/4885SMCHD1 621/4885MYO1G 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.